MDPI and ACS Style
Zajączkowska, R.; Pawlik, K.; Ciapała, K.; Piotrowska, A.; Ciechanowska, A.; Rojewska, E.; Kocot-Kępska, M.; Makuch, W.; Wordliczek, J.; Mika, J.
Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain. Pharmaceuticals 2023, 16, 1023.
https://doi.org/10.3390/ph16071023
AMA Style
Zajączkowska R, Pawlik K, Ciapała K, Piotrowska A, Ciechanowska A, Rojewska E, Kocot-Kępska M, Makuch W, Wordliczek J, Mika J.
Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain. Pharmaceuticals. 2023; 16(7):1023.
https://doi.org/10.3390/ph16071023
Chicago/Turabian Style
Zajączkowska, Renata, Katarzyna Pawlik, Katarzyna Ciapała, Anna Piotrowska, Agata Ciechanowska, Ewelina Rojewska, Magdalena Kocot-Kępska, Wioletta Makuch, Jerzy Wordliczek, and Joanna Mika.
2023. "Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain" Pharmaceuticals 16, no. 7: 1023.
https://doi.org/10.3390/ph16071023